These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35890315)

  • 1. Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.
    Cavalcanti F; Gonzalez-Rey E; Delgado M; Falo CP; Mestre L; Guaza C; O'Valle F; Lufino MMP; Xaus J; Mascaró C; Lunardi S; Sacilotto N; Dessanti P; Rotllant D; Navarro X; Herrando-Grabulosa M; Buesa C; Maes T
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations.
    Maes T; Mascaró C; Rotllant D; Lufino MMP; Estiarte A; Guibourt N; Cavalcanti F; Griñan-Ferré C; Pallàs M; Nadal R; Armario A; Ferrer I; Ortega A; Valls N; Fyfe M; Martinell M; Castro Palomino JC; Buesa Arjol C
    PLoS One; 2020; 15(5):e0233468. PubMed ID: 32469975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
    Maes T; Mascaró C; Tirapu I; Estiarte A; Ciceri F; Lunardi S; Guibourt N; Perdones A; Lufino MMP; Somervaille TCP; Wiseman DH; Duy C; Melnick A; Willekens C; Ortega A; Martinell M; Valls N; Kurz G; Fyfe M; Castro-Palomino JC; Buesa C
    Cancer Cell; 2018 Mar; 33(3):495-511.e12. PubMed ID: 29502954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat.
    Antonijoan RM; Ferrero-Cafiero JM; Coimbra J; Puntes M; Martínez-Colomer J; Arévalo MI; Mascaró C; Molinero C; Buesa C; Maes T
    CNS Drugs; 2021 Mar; 35(3):331-344. PubMed ID: 33755924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
    Noce B; Di Bello E; Fioravanti R; Mai A
    Front Pharmacol; 2023; 14():1120911. PubMed ID: 36817147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ORY-1001, a KDM1A inhibitor, inhibits proliferation, and promotes apoptosis of triple negative breast cancer cells by inactivating androgen receptor.
    Wang T; Zhang F; Sun F
    Drug Dev Res; 2022 Feb; 83(1):208-216. PubMed ID: 34347904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable
    Mascaró C; Ortega A; Carceller E; Ruiz Rodriguez R; Ciceri F; Lunardi S; Yu L; Hilbert M; Maes T
    J Biol Chem; 2019 May; 294(20):8311-8322. PubMed ID: 30804215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actin-Binding Protein Cortactin Promotes Pathogenesis of Experimental Autoimmune Encephalomyelitis by Supporting Leukocyte Infiltration into the Central Nervous System.
    Samus M; Li YT; Sorokin L; Rottner K; Vestweber D
    J Neurosci; 2020 Feb; 40(7):1389-1404. PubMed ID: 31911458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ORY-1001 Suppresses Cell Growth and Induces Apoptosis in Lung Cancer Through Triggering HK2 Mediated Warburg Effect.
    Lu Z; Guo Y; Zhang X; Li J; Li L; Zhang S; Shan C
    Front Pharmacol; 2018; 9():1411. PubMed ID: 30568590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.
    Tremolanti C; Cavallini C; Meyer L; Klein C; Da Pozzo E; Costa B; Germelli L; Taliani S; Patte-Mensah C; Mensah-Nyagan AG
    Mol Neurobiol; 2022 Mar; 59(3):1744-1765. PubMed ID: 35018577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy.
    Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone methyl-transferases and demethylases in the autophagy regulatory network: the emerging role of KDM1A/LSD1 demethylase.
    Ambrosio S; Ballabio A; Majello B
    Autophagy; 2019 Feb; 15(2):187-196. PubMed ID: 30208749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis.
    Martinez B; Peplow PV
    Neural Regen Res; 2020 Oct; 15(10):1831-1837. PubMed ID: 32246624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.
    Blanc CA; Rosen H; Lane TE
    J Neuroinflammation; 2014 Aug; 11():138. PubMed ID: 25138356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of neuronal Lysine-Specific Demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2.
    Toffolo E; Rusconi F; Paganini L; Tortorici M; Pilotto S; Heise C; Verpelli C; Tedeschi G; Maffioli E; Sala C; Mattevi A; Battaglioli E
    J Neurochem; 2014 Mar; 128(5):603-16. PubMed ID: 24111946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes.
    Cuyàs E; Gumuzio J; Verdura S; Brunet J; Bosch-Barrera J; Martin-Castillo B; Alarcón T; Encinar JA; Martin ÁG; Menendez JA
    Aging (Albany NY); 2020 Mar; 12(6):4794-4814. PubMed ID: 32191225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis.
    Musella A; Gentile A; Guadalupi L; Rizzo FR; De Vito F; Fresegna D; Bruno A; Dolcetti E; Vanni V; Vitiello L; Bullitta S; Sanna K; Caioli S; Balletta S; Nencini M; Buttari F; Stampanoni Bassi M; Centonze D; Mandolesi G
    Cells; 2020 May; 9(5):. PubMed ID: 32455907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
    Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
    Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilocarpine-induced seizures associate with modifications of LSD1/CoREST/HDAC1/2 epigenetic complex and repressive chromatin in mice hippocampus.
    Noches V; Rivera C; González MP; Merello G; Olivares-Costa M; Andrés ME
    Biochem Biophys Rep; 2021 Mar; 25():100889. PubMed ID: 33426312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.